38th week of 2013 patent applcation highlights part 46 |
Patent application number | Title | Published |
20130243785 | SELECTIVE REMOVAL OF AGE-MODIFIED CELLS FOR TREATMENT OF ATHEROSCLEROSIS - A method of treating atherosclerosis comprises removing AGE-modified cells from a patient. The AGE-modified cells include erythrocytes, intima cells, endothelial cells, smooth muscle cells, macrophages, and foam cells. A variety of techniques, such as ultrasound and binding with an anti-AGE antibody, may be used to identify and remove the AGE-modified cells. | 2013-09-19 |
20130243786 | TREATMENT OF JUVENILE RHEUMATOID ARTHRITIS (JRA) - Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described. | 2013-09-19 |
20130243787 | Predicting TGF-beta Therapeutic Responses - The invention provides methods of determining whether a cancer in a subject is responsive to anti-TGF-β therapy. In some embodiments, the invention further provides for the administration of an anti-TGF-β therapy cancer therapy to the subject. | 2013-09-19 |
20130243788 | ANTIBODIES TO TGF-BETA - The present invention relates to antibody molecules, in particular antibody molecules that bind. Transforming Growth Factor beta (TGFβ), and uses thereof. More particularly, the invention relates to antibody molecules that bind and preferably neutralise TGβ1, TGFβ2 and TGFβ3, so-called “pan-specific” antibody molecules, and uses of such antibody molecules. Preferred embodiments within the present invention are antibody molecules, whether whole antibody (e.g. IgG, such as IgG1 or IgG4) or antibody fragments (e.g. scFv, Fab, dAb). | 2013-09-19 |
20130243789 | Multiple Gene Expression Including sORF Constructs and Methods with Polyproteins, Pro-Proteins and Proteolysis - Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins. | 2013-09-19 |
20130243790 | Methods Of Treating Obesity By Inhibiting Nicotinamide N-Methyl Transferase (NNMT) - The present invention, in various embodiments, relates to methods of inhibiting NNMT production or activity in a cell, and methods of treating or preventing obesity or a related metabolic condition in a subject in need thereof, comprising administering a nicotinamide N-methyltransferase (NNMT) antagonist. The invention further provides methods of identifying NNMT antagonists useful for treating obesity and related metabolic disorders. | 2013-09-19 |
20130243791 | Pain treatment - The present invention relates generally to a method for the treatment and prophylaxis of pain. In accordance with the present invention, it is proposed that antagonists of GM-CSF are effective in the treatment of pain. Antagonists of GM-CSF include, but are not limited to, antibodies which are specific for GM-CSF or the GM-CSF receptor. The present invention further provides transgenic animals, such as a GM-CSF knock-out mouse, useful for testing antagonists in certain disease models. | 2013-09-19 |
20130243792 | HUMAN BINDING MOLECULES CAPABLE OF BINDING TO AND NEUTRALIZING INFLUENZA B VIRUSES AND USES THEREOF - Described are binding molecules, such as human monoclonal antibodies, that bind to hemagglutinin of influenza B viruses, and have a broad neutralizing activity against such influenza viruses. These binding molecules do not bind to hemagglutinin of influenza A viruses. Further provided are nucleic acid molecules encoding the binding molecules, and compositions comprising the binding molecules. The binding molecules can be used in the diagnosis of, prophylaxis against, and/or treatment of influenza B virus infections. | 2013-09-19 |
20130243793 | Humanized Anti-CXCR5 Antibodies, Derivatives Thereof And Their Use - The present invention relates to humanized antibodies that specifically bind to CXCR5 and can, for example, inhibit CXCR5 function. The invention also includes uses of the antibodies to treat or prevent CXCR5 related diseases or disorders. | 2013-09-19 |
20130243794 | METHODS FOR PREDICTING AND TREATING INFECTION-INDUCED ILLNESSES AND PREDICTING THE SEVERITY OF INFECTION-INDUCED ILLNESSES - The invention provides methods for determining the propensity to develop, or the presence of, one or more infection-induced illness(es). The invention further provides methods of treating an infection (e.g., bacterial infection), methods of diagnosing an infection-induced illness in a subject, and methods of predicting the future severity of one or more infection-induced illness(es). Also provided are kits for determining the likelihood or propensity of a subject to develop one or more infection-induced illness(es) and kits for diagnosing one or more infection-induced illness(es) in a subject and identifying a subject as having an increased risk of later developing one or more severe infection-induced illness(es). | 2013-09-19 |
20130243795 | HUMAN ANTI-CD27 ANTIBODIES, METHODS AND USES - Human antibodies immunospecific for human CD27 are capable of blocking CD27 binding to its ligand CD70 and neutralizing bioactivity of CD27 including, but not limited to, CD27 intracellular signaling, T-cell proliferation and activation, B-cell proliferation and differentiation, plasmablast formation and alleviation of antibody responses, stimulation of tumor cells by CD70, and the production of soluble mediators from T and B-cells. The antibodies are useful in diagnosing or treating CD27 activity associated diseases and conditions. | 2013-09-19 |
20130243796 | GENETIC PRODUCTS DIFFERENTIALLY EXPRESSED IN TUMORS AND USE THEREOF - The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor. | 2013-09-19 |
20130243797 | COMPOSITION COMPRISING HYDROLYSED PROTEINS AND OLIGISACCHARIDES FOR TREATING SKIN DISEASES - The invention discloses a composition comprising at least one N-acetyl lactosamine, at least one sialylated oligosaccharide and at least one fucosylated oligosaccharide, and a hydrolysate comprising partially and/or extensively hydrolysed proteins, for use in the prevention and/or treatment of skin conditions and skin diseases. Preferably said composition is a starter infant formula. Said skin disease is in particular atopic dermatitis. | 2013-09-19 |
20130243798 | PEPTIDES FOR VACCINE AGAINST BIRCH ALLERGY - The present invention relates to compositions comprising peptides for preventing or treating allergy to birch, and in particular to optimal combinations of peptides for preventing or treating said allergy. | 2013-09-19 |
20130243799 | NOVEL CANCER-ASSOCIATED ANTIGEN - The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits. | 2013-09-19 |
20130243800 | HLA-DR-BINDING ANTIGEN PEPTIDE DERIVED FROM WT1 - The present invention provides a method of treating or preventing cancer, by administering a peptide consisting of 16-25 contiguous amino acids in the amino acid sequence of human WT1 of SEQ ID NO: 1, which has the amino acid sequence of SEQ ID NO: 24, an expression vector having a polynucleotide encoding said peptide or a cell containing the expression vector to a subject in need thereof. | 2013-09-19 |
20130243801 | EPITOPE THERAPY FOR INFECTIOUS DISEASES - The present invention relates to a method of treating a subject for an infectious disease. This method involves selecting a subject infected with an infectious disease-causing agent. The infectious disease-causing agent elicits, in the selected subject, an immune response that is insufficient to cure the selected subject of the infectious disease. The method also involves administering to the selected subject a synthetic peptide representing an antigen epitope associated with an immune response to the infectious agent. The immune response to the synthetic peptide is sufficient to treat the selected subject for the infectious disease. | 2013-09-19 |
20130243802 | POLYPEPTIDES WITH AFFINITY FOR HEAT SHOCK PROTEINS (HSPS) AND HSP ASSOCIATED COMPLEXES (HACS) AND THEIR USE IN DIAGNOSIS AND THERAPY - The present application is directed to a peptides comprising an a-helix forming-amino acid sequence that binds a heat shock protein. Also included is a polypeptide comprising (a) a first peptide portion that comprises an α-helix-forming amino acid sequence that binds a heat shock protein; and (b) at least one second peptide portion comprising an antigenic amino acid sequence and/or an a-helix-stabilizing amino acid sequence that increases the interaction of the first peptide portion with the heat shock protein. The present application also includes compositions comprising the peptides and/or polypeptides of present application and uses of the peptides and/or polypeptides of the present application for fractionating substances relevant for discovery, research or clinical analysis from a biological sample and as therapeutics. | 2013-09-19 |
20130243803 | THERAPIES, VACCINES, AND PREDICTIVE METHODS FOR INFECTIOUS SALMON ANEMIA VIRUS - The present invention provides therapies, vaccines, and predictive methods for infectious salmon anemia virus and provides compounds for diagnosing, preventing, and treating outbreaks of infectious salmon anemia virus including compounds for diagnosing, preventing, and treating infectious salmon anemia across different strains of virus. | 2013-09-19 |
20130243804 | Peptide Sequences and Compositions - Provided is a polypeptide having no more than 100 amino acids, which polypeptide comprises one or more sequences having at least 60% homology with any of SEQ ID 1-6, or comprises two or more epitopes having 7 amino acids or more, each epitope having at least 60% homology with a sub-sequence of any of SEQ ID 1-6 that has the same length as the epitope: | 2013-09-19 |
20130243805 | Compositions and Methods for the Treatment or Prevention of Hepatitis B Virus Infection - Disclosed are yeast-based immunotherapeutic compositions, hepatitis B virus (HBV) antigens, and fusion proteins for the treatment and/or prevention of HBV infection and symptoms thereof, as well as methods of using the yeast-based immunotherapeutic compositions, HBV antigens, and fusion proteins for the prophylactic and/or therapeutic treatment of HBV and/or symptoms thereof. | 2013-09-19 |
20130243806 | POLY-N-ACETYL GLUCOSAMINE (PNAG/DPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 2013-09-19 |
20130243807 | NEISSERIA MENINGITIDIS COMPOSITIONS AND METHODS THEREOF - In one aspect, the invention relates to an isolated polypeptide comprising an amino acid sequence that is at least 95% identical to SEQ ID NO: 71. In another aspect, the invention relates to an immunogenic composition including an isolated non-lipidated, non-pyruvylated ORF2086 polypeptide from | 2013-09-19 |
20130243808 | COMPOSITIONS AND METHODS FOR VACCINATING HUMANS AND ANIMALS AGAINST ENVELOPED VIRUSES - Immunogenic compositions and methods for vaccinating humans and animals against enveloped viruses, and more particularly against influenza viruses. Immunogenic compositions are composed of internal moieties of an enveloped virus. Such internal moieties are more highly conserved between different viral strains than are their external moiety counterparts. Consequently, these immunogenic compositions have an increased likelihood of generating immuno-protective responses in humans and animals against enveloped viruses that are strain independent. Methods are also disclosed that increase the ability of the immunogenic compositions to generate immuno-protective responses against their target viruses. | 2013-09-19 |
20130243809 | RECOMBINANT FLAVIVIRAL CONSTRUCTS AND USES THEREOF - A recombinant viral construct for expressing an exogenous polypeptide in a cell and uses thereof are provided. The recombinant viral constructs are derived from Japanese encephalitis virus (JEV). The recombinant viral constructs encodes a fusion protein, which includes an exogenous (i.e., non-JEV) polypeptide and a JEV non-structural protein 1 (JEV NS1) or a segment thereof. Particularly, the exogenous polypeptide is inserted into the carboxyl-terminus of the JEV NS1, and the production of the recombinant fusion protein does not affect viral replication. Upon infection a cell with such recombinant viral constructs, JEV particles comprising limited multiplicative virions (LMV) may be produced. Each LMV comprises the as-described JEV replicon. The JEV particles are useful in eliciting an immune response to the exogenous polypeptide in a host and thereby confer the host with protective immunization against the exogenous polypeptide. | 2013-09-19 |
20130243810 | SYNERGISTIC IMMUNOGENIC COMPOSITIONS BASED ON PROTEIN ANTIGENS COMBINED WITH PERTUSSIS CELL ANTIGEN AND INACTIVATED TOXINS - The present invention relates to synergistic immunogenic compositions for preventing whooping cough and infections caused by | 2013-09-19 |
20130243811 | IMMUNOSTIMULATORY OLIGONUCLEOTIDES AND USES THEREOF - Oligonucleotides containing the non-palindromic sequence motif:
| 2013-09-19 |
20130243812 | Replication-Defective Flavivirus Vaccines and Vaccine Vectors - This invention provides replication-defective flavivirus vaccines and vaccine vectors, and corresponding compositions and methods. | 2013-09-19 |
20130243813 | INTERGENIC REGIONS AS INSERTION SITES IN THE GENOME OF MODIFIED VACCINIA VIRUS ANKARA (MVA) - The present invention relates to novel insertion sites useful for the integration of exogenous sequences into the Modified Vaccinia Ankara (MVA) virus genome. The present invention further provides plasmid vectors to insert exogenous DNA into the genome of MVA. Furthermore, the present invention provides recombinant MVA comprising an exogenous DNA sequence inserted into the new insertion site as medicine or vaccine. | 2013-09-19 |
20130243814 | MICROBIAL DELIVERY SYSTEM - The present invention provides methods and compositions for treating or preventing allergic responses, particularly anaphylactic allergic responses, in subjects who are allergic to allergens or susceptible to allergies. Methods of the present invention utilize administration of microorganisms to subjects, where the microorganisms produce allergens and protect the subjects from exposure to the allergens until phagocytosed by antigen-presenting cells. Particularly preferred microorganisms are gram-negative bacteria, gram-positive bacteria, and yeast. Particularly preferred allergens are proteins found in foods, venoms, drugs and latex that elicit allergic reactions and anaphylactic allergic reactions in individuals who are allergic to the proteins or are susceptible to allergies to the proteins. The proteins may also be modified to reduce the ability of the proteins to bind and crosslink IgE antibodies and thereby reduce the risk of eliciting anaphylaxis without affecting T-cell mediated Th1-type immunity. | 2013-09-19 |
20130243815 | INHIBITORS OF DSRNA-DEPENDENT PROTEIN KINASE (PKR) AS ENHANCERS OF BUNYAVIRUS LIVE-ATTENUATED VACCINES - Certain embodiments of the invention are directed to methods and compositions for inhibiting dsRNA-dependent protein kinase (PKR) and augmenting the immunogenicity of Bunyavirus live-attenuated vaccines. | 2013-09-19 |
20130243816 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising influenza hemagglutinin and neuraminidase variants are provided. | 2013-09-19 |
20130243817 | VACCINE COMPOSITIONS - Present invention relates to vaccine formulations and adjuvants for use in e.g. compositions, thereby avoiding the phenomenon of Bell's palsy in a frequency above the natural occurance. | 2013-09-19 |
20130243818 | Composition Comprising Sortase Anchored Surface Proteins of Streptococcus Uberis - The present invention provides an immunogenic composition comprising one or more | 2013-09-19 |
20130243819 | Methods Relating To An Attenuated Mycoplasma - The present invention provides a method for identifying or generating an attenuated | 2013-09-19 |
20130243820 | MODIFICATION OF EXOSOMAL COMPONENTS FOR USE AS A VACCINE - The presently disclosed subject matter provides modified cell-derived exosomes substantially lacking one or more immunosuppressive polypeptides. The presently-disclosed subject matter further provides methods of producing the modified exosomes and methods of using the modified exosomes for treating cancers. | 2013-09-19 |
20130243821 | SOYBEAN DERIVED HUMAN THYROGLOBULIN, METHODS OF PRODUCING AND APPLICATIONS THEREOF - The present invention includes novel soybean derived human thyroglobulin, methods of producing human thyroglobulin in plants such as soybean, and novel diagnostic applications for the detection and stratification of endocrine malignancies including thyroid cancer and thyroiditis. The invention also includes the use of soybean-derived human thyroglobulin in affinity matrices to remove autoreactive anti-thyroglobulin antibodies from patient's sera prior to analyses. Moreover, the invention also includes methods and compositons of treating, preventing and or/ameliorating symptoms associated with thyroiditis. | 2013-09-19 |
20130243822 | Composition and Method for Healing of Skin Wounds - This invention provides compositions and methods for topically treating skin wounds. The composition comprises C7, C7M, a variant thereof, or a combination thereof in a pharmaceutically acceptable carrier. The method comprises the steps of topically applying compositions of this invention to the skin wound. | 2013-09-19 |
20130243823 | METHODS AND PRODUCTS FOR INCREASING THE RATE OF HEALING OF TISSUE WOUNDS - Disclosed are methods for increasing the rate of healing of a tissue wound by administering a composition including a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting wound healing in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of a tissue wound. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 2013-09-19 |
20130243824 | SUSTAINED RELEASE COMPOSITION CONTAINING SDF-1 - An object of the present invention is to provide a sustained release composition containing SDF-1. The present invention provides a sustained release composition containing (1) SDF-1 and (2) a hydrogel containing modified gelatin having a carboxyl group and/or a sulfo group. Since the composition can release SDF-1, a chemokine which is a capable of promoting accumulation of vascular progenitor cells in vivo, in the sustained manner, it can be useful for treatment and/or suppression of symptom progression of ischemic disease or bone disease, as pharmaceutical preparations in various formulations. | 2013-09-19 |
20130243825 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF SKIN DISEASES - Provided herein are chemical matrices, compositions, and methods for the treatment of skin diseases and disorders in an individual. Said chemical matrices and compositions comprise an alcohol selected from ethanol, isopropanol or n-propanol, at least one excipient, and, a corticosteroid, wherein the alcohol is distributed within the chemical matrix as a microbubble and the corticosteroid is present in less than the standardized topical corticosteroid concentration. Additionally, methods are described for the use of said chemical matrices and compositions for the treatment of skin diseases and disorders. | 2013-09-19 |
20130243827 | Drug Loaded Polymeric Nanoparticles and Methods of Making and Using Same - The present disclosure generally relates to methods of making nanoparticles having about 0.2 to about 35 weight percent of a therapeutic agent; and about 10 to about 99 weight percent of biocompatible polymer such as a diblock poly(lactic) acid-poly(ethylene)glycol. | 2013-09-19 |
20130243828 | CATIONIC DRY POWDERS - The invention relates to respirable dry particles that contain one or more divalent metal cations, such as calcium, in an amount of less than 3% by weight, and to dry powders that contain the respirable particles. The dry particles can further contain an active agent, or can be used as carrier particles to deliver an active agent. | 2013-09-19 |
20130243829 | ENHANCEMENT OF IMMUNE RESPONSE BY TRANSFER FACTOR - In certain aspects, methods and kits are provided for use in enhancement of immune response by administering to a subject an effective amount of a composition containing at least one transfer factor. | 2013-09-19 |
20130243830 | Stable Corticosteroid Nanoparticulate Formulations and Methods for the Making and Use thereof - Disclosed are stable corticosteroid nanoparticulate formulations, methods of making and therapeutic uses thereof. | 2013-09-19 |
20130243831 | MODIFIED PECTINS, COMPOSITIONS AND METHODS RELATED THERETO - The present invention provides compositions of modified pectin and methods for preparing and using them. | 2013-09-19 |
20130243832 | POLY(VINYL BENZOATE) NANOPARTICLES FOR MOLECULAR DELIVERY - The present invention comprises poly(vinyl benzoate) nanoparticle suspensions as molecular carriers. These nanoparticles can be formed by nanoprecipitation of poly(vinyl benzoate) in water using Pluronic F68 as surfactant, to create spherical nanostructures measuring about 200-250 nm in diameter which are stable in phosphate buffer and blood serum, and only slowly degrade in the presence of esterases. Kinetics experiments in phosphate buffer indicate that 78% of the coumarin-6 was encapsulated within the polymer matrix of the nanoparticle, and the residual 22% of coumarin-6 was surface-bound and quickly released. The nanoparticles are non-toxic in vitro towards human epithelial cells (IC | 2013-09-19 |
20130243833 | COMPRESSED FORMULATIONS OF ORDERED MESOPOROUS SILICAS - A compressed formulation comprising an ordered mesoporous silica loaded with an active ingredient, a combination of microcrystalline cellulose (MCC) and croscarmellose sodium, and optional further excipients. | 2013-09-19 |
20130243834 | CROSS LINKED SILICONE COPOLMYER NETWORKS IN A THICKENED AQUEOUS PHASE - A thickened aqueous composition in the form of an emulsion that has from about 1% to about 10% of an acrylate cross linked silicone copolymer network, and from about 0.01% to about 10% of a gum, clay, cellulose, modified cellulosic composition, and mixtures thereof; and from about 20% to about 97% of water. | 2013-09-19 |
20130243835 | SUPERABSORBENT POLYMERS AND SILICONE ELASTOMER FOR USE IN SKIN CARE COMPOSITIONS - A thickened aqueous composition containing from about 0.01% to about 10%, by weight, of an superabsorbent polymer, from about 0.1% to about 20%, of a silicone elastomer; and from about 20% to about 98% of water. | 2013-09-19 |
20130243836 | SUPERABSORBENT POLYMERS AND SUNSCREEN ACTIVES FOR USE IN SKIN CARE COMPOSITIONS - A skin care composition having from about 0.01% to about 5%, by weight, of an superabsorbent polymer which is a sodium polyacrylate, sodium polacrylate starch, sodium acrylates crosspolymer-2 or mixtures of these and a portion of the polymer comprises a grafted starch material. The superabsorbent polymer is particulate where the particles have an average particle size in the range of from about 5μ-30μ, and the individual particles in their dry or un-swollen condition are substantially non-spherical, flat, platelet, or elongated in shape. The particles have an absorption capacity of at least about 1000 times their initial dry or un-swollen volume. Additionally, the skin care composition contains from about 0.01-10% of a dry powder that is either starch or silicone based and wherein the dry powder is coated with a silicone based material. Further there is provided a UV active. | 2013-09-19 |
20130243837 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging - Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours. | 2013-09-19 |
20130243838 | BREATH FRESHENING CONFECTIONERY PRODUCTS AND METHODS OF MAKING AND USING SAME - A confectionery product comprises a first side and a second side generally opposite to said first side, and a product thickness. The second side comprises an abrasive surface that is suitable for cleaning the top surface of a tongue within an oral cavity. The second side has a width and a length, the smallest of which is at least 1.6 times the product thickness. The product does not include a handle and the product does not include a combination of a soft confectionery with a hard confectionery. In some embodiments the first side is smooth, and may be domed shaped and generally fit the roof of the mouth. The abrasive surface may be provided by 1) a formed, uneven surface, 2) including abrasive particles in the composition making up the second surface, or 3) a combination of a formed, uneven surface and abrasive particles. The confectionery product may be a hard confectionery, but may also be a chewing gum product. | 2013-09-19 |
20130243839 | Controlled, Sustained Release Particles for Treating Seeds and Plants and Methods for Making the Particles - The invention relates to active particles, including core-shell particles, having low burst, controllable, sustained release which are useful for coating seeds. The active particles can also be used in sprayable and dry formulations for treating soil or plants. The particulate coating can also contain inert organic or inorganic material. The invention also relates to methods for preparing the active particles. The methods include: adding additional material to core particles to form a shell, removing active ingredient from a core surface to create an active-depleted shell, and crosslinking the outer layers of a core to form a shell. | 2013-09-19 |
20130243840 | INCORPORATION OF PARTICULATE CERAGENINS IN POLYMERS - A composite that includes a polymeric material having a void structure and particulate ceragenin material (i.e., ceragenin particles) associated with the void structure. The average particle size of the ceragenin particles in the composite is in a range from 5 nm to 20 μm, 50 nm to 10 μm, 100 nm to 5 μm, or 1 μm to 10 μm. The composite has a high loading of ceragenin particles (e.g., about 10% to about 25%, by weight). The composite has good polymer stability, the ability to release ceragenins from the ceragenin particles disposed in the composite over a sustained period of time at a characteristic elution rate, and the ability to kill large numbers of bacteria and other susceptible microbes over the sustained period of time. | 2013-09-19 |
20130243841 | CONCENTRATION OF VACCINE ANTIGENS WITH LYOPHILIZATION - A process for preparing a lyophilised vaccine antigen, comprising steps of (i) increasing the concentration of an antigen in a liquid composition including that antigen using centrifugal filtration and/or ultrafiltration, to provide a concentrated antigen, and (ii) lyophilising the concentrated antigen, to provide the lyophilised vaccine antigen. The lyophilised material can be reconstituted and used for vaccine formulation. The process is particularly useful with influenza vaccine antigens. | 2013-09-19 |
20130243842 | COMPOSITIONS AND METHODS FOR TREATING BONE DISEASES AND BROKEN BONES - Disclosed herein are methods of promoting osteogenesis in a subject, comprising administering a composition comprising a therapeutically effective amount of at least one cationic steroid antimicrobial (CSA). Also disclosed herein are methods of promoting osteogenesis in a subject in need of such promotion, comprising administering a composition comprising a therapeutically effective amount of at least one CSA. Additionally, disclosed herein are compounds and compositions comprising at least one CSA, or a pharmaceutically acceptable salt thereof, for use in the treatment of bone disease or the treatment of broken bones. Kits comprising such compositions and instructions on such methods are also contemplated herein. | 2013-09-19 |
20130243843 | Vitronectin:Keratinocyte Growth Factor Chimeras - Isolated protein complexes are provided comprising keratinocyte growth factor and vitronectin, or at least domains thereof that enable binding to and activation of both a keratinocyte growth factor receptor and an integrin receptor for vitronectin. These protein complexes include synthetic proteins where the keratinocyte growth factor and vitronectin sequences are joined by a linker sequence. In particular forms, vitronectin sequences do not include a C-terminal heparin binding domain. Also provided are uses of these protein complexes for stimulating or inducing cell migration and/or proliferation in wound healing, tissue engineering, cosmetic and therapeutic treatments such as skin replacement, skin replenishment and treatment of burns where epithelial cell migration is required. In other embodiments, the invention provides inhibition of cancer cell metastasis, particularly in relation to breast cancer. | 2013-09-19 |
20130243844 | Drug Depots Having Different Release Profiles for Reducing, Preventing or Treating Pain and Inflammation - Effective treatments of pain and/or inflammation are provided. Through the administration of an effective amount of at least analgesic and/or at least one anti-inflammatory agent at or near a target site, one can reduce, prevent or treat inflammation and pain. | 2013-09-19 |
20130243845 | NUTRACEUTICAL CHOCOLATE OR COMPOUND CHOCOLATE PRODUCT - The subject invention relates to a chocolate or compound chocolate product comprising added functional ingredients including vitamin C, vitamin E, zinc, copper and, optionally, a xanthophyll. The invention further concerns the production of such chocolates and compound chocolate products, their assembly in kit formats and the use of these products for the therapy of diseases of the eye, in particular macular degeneration and cataract formation, or for the maintenance and support of general eye health. | 2013-09-19 |
20130243846 | PRESS-CONTACT TYPE IMMERSING INTERLAYER TISSUE - A press-contact type soaked interlayer tissue includes face towel sheets. The face towel sheet comprises two layers of face towel sheet parts ( | 2013-09-19 |
20130243847 | ACTIVATED CREATININE AND PRECURSORS THEREOF AS ANTIBACTERIAL AGENTS, COMPOSITIONS AND PRODUCTS CONTAINING SUCH AGENTS AND USE THEREOF - Creatinine, creatinine precursors or the pharmaceutically acceptable salts thereof are activated to function as an antibacterial agent which has broad spectrum activity and is beneficially used in a variety of applications, such as antimicrobial wound dressings, compositions for topical delivery of the antibacterial agent and for preventing and/or inhibiting the occurrence or spread of bacterial infection, as well as the growth of odor-causing bacteria, to name a few. | 2013-09-19 |
20130243848 | NANOPARTICLES, NANOPARTICLE DELIVERY METHODS, AND SYSTEMS OF DELIVERY - In accordance with the purpose(s) of the present disclosure, as embodied and broadly described herein, embodiments of the present disclosure, in one aspect, relate to nanoparticles, compositions including nanoparticles, methods of making nanoparticles, and the like. In particular, embodiments of the present disclosure include nanoparticles and compositions for the sustained release (e.g., release at a predetermined rate to maintain a certain concentration for a certain period of time) of an agent, such as a small interfering RNA (siRNA) from the nanoparticle. | 2013-09-19 |
20130243849 | Compositions And Methods For Inhibiting Expression Of The HAMP Gene - The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of the HAMP gene (HAMP gene), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of the HAMP gene. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by HAMP gene expression and the expression of the HAMP gene using the pharmaceutical composition. | 2013-09-19 |
20130243850 | ADJUVANT - The present invention relates, in general, to human immunodeficiency vims (HIV- | 2013-09-19 |
20130243851 | EXTRUSION ENCAPSULATION OF ACTIVES AT AN INCREASED LOAD, USING SURFACE ACTIVE PLANT - A glassy extrusion encapsulation composition and a method of making the composition are provided. The encapsulation composition comprises an encapsulate encapsulated in a glassy matrix comprising 0.5 to 12% by weight, based on the total weight of the glassy matrix, of at least one surface active plant extract, and 88 to 99.5% of at least one carbohydrate. The addition of a surface active plant extract to a carbohydrate matrix markedly increases the load of an encapsulate in the encapsulation composition. Such glassy matrices are useful for encapsulation of encapsulates, for example, flavors and medications. A food composition containing the encapsulation composition is also provided. | 2013-09-19 |
20130243852 | ADJUVANT COMPOSITIONS AND METHODS OF POTENTIATING HDAC INHIBITORS USED TO TREAT VARIOUS DISEASES - A composition and method for potentiating, sensitizing, and/or amplifying at least one HDAC inhibitor targeting at least one disease in a patient is provided. In one embodiment, the composition is administered to potentiate, sensitize and/or amplify an HDAC inhibitor targeting at least one cancer. | 2013-09-19 |
20130243853 | COMPOSITIONS AND METHODS FOR TREATING MYELOFIBROSIS - Provided herein are compositions and methods for treating myelofibrosis in a subject. The methods comprise administering to the subject an effective amount of compound which is which is N-tert-butyl-3-[(5-methyl-2-{[4-(2-pyrrolidin-1-ylethoxy)phenyl]amino}pyrimidin-4-yl)amino]benzenesulfonamide or a pharmaceutical salt thereof or a hydrate thereof. | 2013-09-19 |
20130243854 | NOVEL FORMULATION OF INDOMETHACIN - The present invention relates to methods for producing particles of indomethacin using dry milling processes as well as compositions comprising indomethacin, medicaments produced using indomethacin in particulate form and/or compositions, and to methods of treatment of an animal, including man, using a therapeutically effective amount of indomethacin administered by way of said medicaments. | 2013-09-19 |
20130243855 | Modified coagulation factor IX polypeptides and use thereof for treatment - Provided are modified factor IX (FIX) polypeptides and methods of generating modified FIX polypeptides. Also provided are pharmaceutical compositions, including compositions formulation for oral administration, that contain the modified FIX polypeptides, and methods of treatment using modified FIX polypeptides. | 2013-09-19 |
20130243856 | ORAL DRUG DELIVERY SYSTEM - An oral drug delivery system comprising a coated tablet having one or more surfaces. The coated tablet further comprises a core and a coating surrounding the core. The core comprises an active ingredient composition comprising at least one active ingredient and a pharmaceutically acceptable excipient and a swellable composition located in an immediate vicinity of one or more preselected surfaces. The coating comprises a defect wherein said defect is not a passageway through the preselected portion of the coating and operable to be reliably removed fully from the one or more of the preselected surfaces of the tablet upon contact with an aqueous environment, but not removed from at least one of the surfaces. | 2013-09-19 |
20130243857 | THERAPEUTIC COMPOSITIONS COMPRISING RILPIVIRINE HCL AND TENOFOVIR DISOPROXIL FUMARATE - The invention provides multilayer tablets that contain rilpivirine hydrochloride, emtricitabine, and tenofivir disoproxil fumarate. The tablets are useful for the treatment of HIV. | 2013-09-19 |
20130243858 | COMPOUND FORMULATIONS - Solid dosage forms of methylthioninium chloride (MTC) further comprise at least one diluent suitable for direct compression. The MTC exists in a substantially pure and stable polymorphic form. The solid dosage forms may preferably be prepared by direct compression methods. | 2013-09-19 |
20130243859 | ORALLY DISINTEGRATING TABLET - The present invention relates to a multi-layer orally disintegrating tablet having (1) an enteric fine granule-containing layer containing a proton pump inhibitor and (2) an acetylsalicylic acid-containing layer, which shows high stability of the active ingredients (proton pump inhibitor, aspirin) and expresses the pharmacological effects of the active ingredients stably and rapidly after administration. | 2013-09-19 |
20130243860 | STANDARDIZED PLANT EXTRACT, PROCESS FOR OBTAINING THE SAME AND USES THEREOF - The present invention refers to a process for obtaining a standardized extract having antinociceptive, anti-inflammatory and antipyretic properties, from at least one part of a plant of genus | 2013-09-19 |
20130243861 | PRESS-COATED TABLETS OF PREDNISONE - The present invention provides for press-coated tablets of prednisone comprising a core comprising prednisone and a coating around the core. The present invention particularly discloses thickness of the coating applied to core having a convex shape for chronotherapeutic use. The present invention also provides for a process for preparing a press-coated tablet of prednisone and a method for treating conditions or pathology, the symptoms of which occur early in the morning. | 2013-09-19 |
20130243862 | PHOTOCHEMICAL ACTIVATION OF SURFACES FOR ATTACHING BIOMATERIAL - A water-soluble photo-activatable polymer including: a photo-activatable group adapted to be activated by an irradiation source and to form a covalent bond between the water-soluble photo-activatable polymer and a matrix having at least one carbon; a reactive group adapted to covalently react with a biomaterial for subsequent delivery of the biomaterial to a cell; a hydrophilic group; and a polymer precursor. A composition including a monomolecular layer of the water-soluble photo-activatable polymer and a matrix having at least one carbon, wherein the monomolecular layer is covalently attached to the matrix by a covalent bond between the photo-activatable group and the at least one carbon. The composition further includes a biomaterial having a plurality of active groups, wherein the biomaterial is covalently attached to the monomolecular layer by covalent bonding between the active groups and reactive groups. Also provided is a method for delivery of a biomaterial to a cell. | 2013-09-19 |
20130243863 | Stable Formulations for Lyophilizing Therapeutic Particles - The present disclosure generally relates to lyophilized pharmaceutical compositions comprising polymeric nanoparticles which, upon reconstitution, have low levels of greater than 10 micron size particles. Other aspects of the invention include methods of making such nanoparticles. | 2013-09-19 |
20130243864 | COMPOSITIONS AND THEIR USE TO TREAT COMPLICATIONS OF ANEURYSMAL SUBARACHNOID HEMORRHAGE - The described invention provides a method for treating an interruption of a cerebral artery in a subarachnoid space at risk of interruption caused by brain injury in a mammal, which reduces signs or symptoms of at least one delayed complication associated with brain injury using a flowable sustained release particulate composition. | 2013-09-19 |
20130243865 | Antidiabetic Solid Pharmaceutical Compositions - Provided are pharmaceutical compositions in solid form comprising a selective modulator of PPAR-Y suitable for oral dosage to treat subjects having PPAR-Y mediated conditions. Provided further are methods of manufacturing the compositions, and methods of treating a PPAR-Y mediated condition. | 2013-09-19 |
20130243866 | SILK MICROSPHERES FOR ENCAPSULATION AND CONTROLLED RELEASE - A method was developed to prepare silk fibroin microspheres using lipid vesicles as templates to efficiently load therapeutic agents in active form for controlled release. The lipids are subsequently removed through the use of a dehydration agent, such as methanol or sodium chloride, resulting in β-sheet structure dominant silk microsphere structures having about 2 μm in diameter. The therapeutic agent can be entrapped in the silk microspheres and used in pharmaceutical formulations for controlled-release treatments. | 2013-09-19 |
20130243867 | MICELLE COMPOSITIONS AND METHODS FOR THEIR USE - Provided herein is a micelle composition comprising a polyethylene glycol (PEG), a DC-cholesterol, and a dioleoylphosphatidyl-ethanolamine (DOPE) and either or both a pharmaceutical compound core and a polynucleotide coating. Also provided herein is a method of administering one or more compounds to a cell comprising administering to the cell a micelle composition comprising 1) PEG-PE, a DC-cholesterol, and DOPE, and 2) the one or more compounds, wherein the compounds are selected from the group consisting of a polynucleotide and a pharmaceutical composition. Further provided are methods for detecting the micelle composition. | 2013-09-19 |
20130243868 | NOVEL FORMULATIONS - Nanoparticles comprising T3 and their use in treating, e.g., cardiac conditions, for example cardiac arrest, are provided. Such nanoparticles provide improved delivery of T3 and allow for acute treatment and optionally for sustained release of T3 in a patient. | 2013-09-19 |
20130243869 | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME - The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. | 2013-09-19 |
20130243870 | HYDROXYALKYL CELLULOSE - The present invention provides a hydroxyalkyl cellulose having a viscosity of 1.10 mPa·s to 1.95 mPa·s in a 2%-concentration aqueous solution at 20° C., and a solid formulation containing the hydroxyalkyl cellulose. | 2013-09-19 |
20130243871 | DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME - The invention relates to dosage forms that provide prolonged therapy. In particular, the invention relates to dosage forms including various pluralities of drug-containing resin particles. The invention also relates to methods of making these dosage forms and methods of treating using these dosage forms. | 2013-09-19 |
20130243872 | PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR AND ASPIRIN - Provided is a pharmaceutical composite formulation for preventing or treating cardiovascular diseases, which comprises (1) a first particle comprising an HMG-CoA reductase inhibitor and a basic additive; and (2) a second particle comprising a core containing aspirin and an enteric coating layer coated on said core, wherein the difference in the average diameters of said first and second particles is 100 μm to 800 μm; a method for preparing same; and a method of validating the quality of same. The pharmaceutical composite formulation according to the present invention can improve the stability of an active ingredient and prevent adverse impacts between the active ingredients to thereby enable an accurate quality validation of the pharmaceutical composite formulation. | 2013-09-19 |
20130243873 | IMMUNOMODULATORY COMPOSITIONS - Immunomodulator formulations for use in the treatment of disease of the GI tract. The formulations comprise a hydroxylase inhibitor and/or an immunosuppressant. Exemplary formulations comprise hydralazine as a hydroxylase inhibitor and/or cyclosporin A as an immunosuppressant. | 2013-09-19 |
20130243874 | NANOPARTICLES COATED WITH AMPHIPHILIC BLOCK COPOLYMERS - The present provides amphiphilic block copolymer coated surfaces (e.g., nanoparticles, medical devices, etc.) and methods of preparing such surfaces. In certain embodiments, the present invention provides amphiphilic block copolymer coated single dispersed nanoparticles, which are stable in buffer (e.g., PBS) and have neutral but functionable surfaces, and methods of preparing the same. | 2013-09-19 |
20130243875 | THREO-DOPS CONTROLLED RELEASE FORMULATION - The present invention relates to pharmaceutical formulations for the controlled delivery of threo-3-(3,4-dihydroxyphenyl)serine (threo-DOPS) and derivatives of it. Such formulations can contain an extended or slow release component that maintains therapeutic concentration of threo-DOPS in the blood plasma over a prolonged time period. They can be further combined with an immediate release formulation to produce a product that, when administered to a patient in need thereof, results in substantially steady levels of active drug, eliminating the sharp peaks and troughs in blood plasma drug levels experienced with the existing threo-DOPS formulations. | 2013-09-19 |
20130243876 | MIR-200 FAMILY INDUCES MESENCHYMAL-TO-EPITHELIAL TRANSITION (MET) IN OVARIAN CANCER CELLS - The present invention provides a method of treating an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to treat the ovarian cancer. Also provided are methods of preventing metastasis of an ovarian cancer, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to prevent metastasis. Further provided are methods of sensitizing an ovarian cancer to a cytotoxic therapy, the method comprising delivering one or more miR-200 family members to a mammalian subject in need thereof in an amount effective to sensitize the ovarian cancer to the cytotoxic therapy. The invention also contemplates methods of reducing epithelial-to-mesenchymal transition (EMT) in an ovarian cancer or cancer cell as well as methods of inducing mesenchymal-to-epithelial transition (MET). | 2013-09-19 |
20130243877 | Spray-Dried Human Plasma - The technology relates to spray dried plasma and methods of making the same. The method includes providing plasma to a spray drying apparatus, spray drying the plasma, at the spray drying apparatus, to form physiologically active plasma power, the spray drying apparatus configured utilizing one or more parameters, and storing the physiologically active plasma powder. | 2013-09-19 |
20130243878 | BIOMATERIALS FOR DELIVERY OF BLOOD EXTRACTS AND METHODS OF USING SAME - The disclosure provides biomaterials including scaffolds that include blood products including blood fractions and products including platelets for administration to subjects in need thereof. More specifically, the scaffolds based on step growth polymers are enriched with blood extracts that contain platelet rich plasma (PRP) and/or extracts of platelets. Compositions comprising a biomaterial or precursor thereof and a blood extract are provided, as are methods of making and using the biopolymers or precursors thereof. Kits and articles of manufacture comprising the biopolymers or precursors thereof are also described. | 2013-09-19 |
20130243879 | PLATELET RICH PLASMA FORMULATIONS AND USE THEREOF - Compositions for platelet rich plasma (PRP), depleted in neutrophils, are provided. Generally, these compositions comprise a higher concentration of platelets, lymphocytes and monocytes than whole blood with selective depletion of neutrophils to a concentration of less than about 5000/μl. These compositions may have depressed concentrations of red blood cells and hemoglobin. In some variations, the compositions may be useful to treat damaged connective tissue and/or to slow or stop cardiac apoptosis after a heart attack. The PRP composition may be delivered in conjunction with reperfusion therapy. | 2013-09-19 |
20130243880 | PHARMACEUTICAL COMPOSITION AND METHOD OF PREPARING SAME - An object of the present invention is to provide a pharmaceutical composition comprising an enzyme-treated human serum which is useful for treatment and prevention of diseases such as a cancer and an infectious disease, and a method of preparing the same. The present invention relates to a method of preparing a pharmaceutical composition comprising an enzyme-treated human serum, comprising a step of bringing the human serum into contact with β-galactosidase and, to a pharmaceutical composition comprising an enzyme-treated human serum obtained by the preparation method. | 2013-09-19 |
20130243881 | BIOLOGICALLY ACTIVE FOOD ADDITIVE FOR PREVENTING CARDIOVASCULAR DISEASES AND REINFORCING THE CARDIOVASCULAR SYSTEM - The biologically active food additive comprises hawthorn flowers and/or berries and/or leaves and royal jelly in the following ingredient ratio: from 10 mass % to 90 mass % of hawthorn; from 10 to 24 mass % of royal jelly; and from 0 mass % to 70 mass % of fillers. The additive is produced in powder, tablet or capsule form, or aqueous-alcoholic extract form. The complex system of biologically active substances contained in the proposed biologically active food additive not only exerts an effect on the entire cardiovascular system, but also reduces the causes of cardiovascular diseases and improves quality of life in old age by acting on the pathology of the human body. This long-acting agent for prophylaxis and planned health improvement has no contraindications or side effects even during long-term use (more than one year). | 2013-09-19 |
20130243882 | PHARMACEUTICAL COMPOSITION FOR TREATING SKIN WOUND - The present invention provides a method for treating a skin wound in a subject, which comprises administering the skin wound with a composition comprising umbilical mesenchymal stem cells. More particularly, the composition is used for improving wound healing. | 2013-09-19 |
20130243883 | STABLE FORMULATIONS - Described herein are aqueous formulations with stabilized reactive and/or radical species. | 2013-09-19 |
20130243884 | Medical Treatment Kit and Methods of Use Thereof - A medical treatment kit and methods of use thereof is provided. The kit includes a container, two or more chambers within the container, an antiseptic agent disposed in one of the chambers, a cleansing agent disposed in a separate chamber and an applicator. The agents are not contacted until immediate use of the kit is required. The medical treatment kit is used to administer an antiseptic shampoo or other medical composition to a patient with an open wound or injury. The kit is designed to be simple to use in an emergency situation. The kit is also designed to deliver medical compositions that are at the peak of potency. | 2013-09-19 |
20130243885 | Decontamination solution and its use for denaturation, modification, degradation, solubilisation and removal of proteins, nucleic acid molecules and microorganisms - The invention concerns a three component system comprising surface-active substances, vitamins and metal ions for efficient destruction and removal of contaminating proteins, nucleic acids and microorganisms from surfaces like for example laboratory benches, floors, equipment and instruments. These non-corrosive and non-toxic solutions for removal of proteins, nucleic acids and microorganisms are applied by spraying, rubbing or immersion of contaminated surfaces thereby destroying, solubilizing inactivating and removing proteins and nucleic acids. In that way also microorganisms are killed with high efficiency and at the same time all genetic information is inactivated. | 2013-09-19 |